NEXLIZET (bempedoic acid/ezetimibe)

About Esperion Therapeutics

Esperion Therapeutics' mission is to deliver oral, once-daily, non-statin medicines for patients with elevated LDL-C. Its key achievement is the successful FDA approval and commercialization of bempedoic acid (NEXLETOL) and its combination with ezetimibe (NEXLIZET), establishing a new therapeutic class. The company's strategy combines direct U.S. commercialization with ex-U.S. partnerships to maximize global reach while advancing a pipeline of next-generation lipid-modifying agents. Esperion aims to become a leading cardiometabolic company by addressing broader patient populations and complementary risk factors.

Therapeutic Areas

Other LDL-C lowering in HeFH/ASCVD Drugs